menu
    • menu
    [{"orgOrder":0,"company":"SoVarGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SVG101","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"SoVarGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SoVarGen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SoVarGen \/ Undisclosed"},{"orgOrder":0,"company":"SoVarGen","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2025","type":"Agreement","leadProduct":"SVG105","moa":"mTOR","graph1":"Neurology","graph2":"Preclinical","graph3":"SoVarGen","amount2":0.55000000000000004,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.55000000000000004,"dosageForm":"Undisclosed","sponsorNew":"SoVarGen \/ Angelini Pharma","highestDevelopmentStatusID":"4","companyTruncated":"SoVarGen \/ Angelini Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by SoVarGen

    Menu

    SoVarGen

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SoVarGen

                            South Korea arrow
                            The MedTech Conference
                            Not Confirmed

                            SoVarGen

                            South Korea arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SVG105

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Angelini Pharma

                            Deal Size : $550.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Angelini Pharma Signs Exclusive Option Agreement With Sovargen

                            Details : Angelini Pharma and Sovargen will collaboratively lead the pre-clinical development efforts for SVG105, a potentially first-in-class anti-sense oligonucleotide technology to target mTOR pathways.

                            Product Name : SVG105

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            September 22, 2025

                            Lead Product(s) : SVG105

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Angelini Pharma

                            Deal Size : $550.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SoVarGen

                            South Korea arrow
                            The MedTech Conference
                            Not Confirmed

                            SoVarGen

                            South Korea arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SVG101

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg in Healthy Adults

                            Details : SVG101 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 05, 2022

                            Lead Product(s) : SVG101

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth